The purpose of this study is to investigate the use of insulin icodec in the real-world setting in a population that broadly reflects people living with T2D and for whom switching to a once-weekly insulin icodec has been deemed relevant and beneficial by the treating physician. The study will last for approximately 30 weeks.
Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to protocol).
The decision to initiate treatment with commercially available insulin icodec has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include participant in this study.
Male or female, age above or equal to 18 years at the time of signing informed consent.
Diagnosed with T2D greater than or equal to (≥) 1 year before signing informed consent.
Previous participation in this study. Participation is defined as having given informed consent in this study.
Treatment with any investigational drug within 30 days prior to enrolment into study.
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Novo Nordisk A/S
Lead sponsor